Aquestive Therapeutics
AQST
47 hedge funds and large institutions have $21.5M invested in Aquestive Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 13 closing their positions.
673% more call options, than puts
Call options by funds: $286K | Put options by funds: $37K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0.13% more ownership
Funds ownership: 34.11% → 34.24% (+0.13%)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
13% less funds holding
Funds holding: 54 → 47 (-7)
32% less capital invested
Capital invested by funds: $31.5M → $21.5M (-$9.97M)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$6.26M |
| 2 |
Corient Private Wealth
Miami,
Florida
|
+$786K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$667K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$239K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$427K |
| 2 |
Millennium Management
New York
|
-$225K |
| 3 |
Man Group
London,
United Kingdom
|
-$221K |
| 4 |
Renaissance Technologies
New York
|
-$174K |
| 5 |
Two Sigma Investments
New York
|
-$158K |
AQST Hedge Fund Activity: Q3 2023 in Review
47 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2023, worth a combined $21.5M — down 32% from $31.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of AQST and 6 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was Armistice Capital, adding an estimated $6.26M. The largest seller was Walleye Capital, cutting an estimated $427K.
- 47 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2023, down from 54 in Q2 2023.
- Funds reported $21.5M of Aquestive Therapeutics stock for Q3 2023, down 32% quarter-over-quarter.
- 6 funds opened new Aquestive Therapeutics positions in Q3 2023 and 13 closed out, a net change of -7 holders.
- The largest Aquestive Therapeutics buyer in Q3 2023 was Armistice Capital, an estimated $6.26M added.
- The largest Aquestive Therapeutics seller in Q3 2023 was Walleye Capital, an estimated $427K sold.
Based on aggregated 13F filings for Q3 2023.